• Nuvation Bio posted revenue of USD 31.69 million for the quarter ended June 30, 2026, up 555.58% year over year.
• Product revenue climbed to USD 23.19 million from USD 1.24 million; collaboration and license agreements revenue rose to USD 8.5 million from USD 3.6 million.
• Total costs and expenses increased 20.9% to USD 82.72 million, led by selling, general and administrative expense of USD 42.59 million and R&D of USD 30.66 million.
• Other expense widened to USD 11.8 million from other income of USD 4.58 million, driven by a USD 9.47 million loss on debt extinguishment.
• Completed a USD 287.5 million offering of 0.75% Convertible Senior Notes due 2032, with net proceeds of about USD 279.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336646), on August 06, 2026, and is solely responsible for the information contained therein.